Sarclisa data could reshape myeloma treatment landscape

Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s (Euronext: SAN) Sarclisa (isatuximab) in multiple myeloma.

Results from the IMROZ and GMMG-HD7 Phase III studies demonstrated Sarclisa’s potential to deliver deeper and longer-lasting responses in both transplant-ineligible and transplant-eligible patients.

The findings come months after the US Food and Drug Administration approved Sarclisa to be used with chemo for newly diagnosed multiple myeloma patients who are ineligible for stem cell transplantation.